Literature DB >> 24272804

Peptides and proteins as drugs.

B L Ferraiolo1, L Z Benet.   

Abstract

Relatively small modifications of clinically useful endogenous compounds have been shown to have therapeutically beneficial effects on their pharmacodynamic and pharmacokinetic properties. These effects include increased potency and effect selectivity, and prolonged duration of action. In addition, these modifications have resulted in compounds that can be administered orally where only parenteral administration was previously possible. One type of modification resulting in distinctive properties is exemplified by the hybrid interferons produced by the recombination of segments of genes coding for different molecular species. Chemical modification has also resulted in many examples of analogs of natural peptides that are more potent, more selective and more stable than the endogenous compounds. Conjugation to peptide or protein carriers is a third method used to selectively modify the properties of an endogenous compound. The carriers that have been used include synthetic polypeptides, endogenous proteins, toxins and monoclonal antibodies. The effect that covalent attachment to a carrier has on the properties of a ligand is highly dependent upon the carrier, the ligand and the linkage between them.

Year:  1985        PMID: 24272804     DOI: 10.1023/A:1016327803573

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  57 in total

1.  D-Trp8-somatostatin: an analog of somatostatin more potent than the native molecule.

Authors:  J Rivier; M Brown; W Vale
Journal:  Biochem Biophys Res Commun       Date:  1975-07-22       Impact factor: 3.575

2.  Evidence for analgesic activity of enkephalin in the mouse.

Authors:  H H Buscher; R C Hill; D Römer; F Cardinaux; A Closse; D Hauser; J Pless
Journal:  Nature       Date:  1976-06-03       Impact factor: 49.962

3.  Monoclonal antibody toxin conjugates for experimental graft-versus-host disease prophylaxis. Reagents selectively reactive with T cells and not murine stem cells.

Authors:  D A Vallera; R J Youle; D M Neville; C C Soderling; J H Kersey
Journal:  Transplantation       Date:  1983-07       Impact factor: 4.939

4.  The potential of monoclonal antibodies as carriers of radiation and drugs for immunodetection and therapy of brain tumors.

Authors:  M A Bourdon; R E Coleman; D D Bigner
Journal:  Prog Exp Tumor Res       Date:  1984

5.  Insulin-ricin B chain conjugate. A hybrid molecule with ricin-binding activity and insulin biological activity.

Authors:  R A Roth; B A Maddux; K Y Wong; Y Iwamoto; I D Goldfine
Journal:  J Biol Chem       Date:  1981-06-10       Impact factor: 5.157

6.  Production of a macromomycin (MCR)-monoclonal antibody conjugate and its biological activity.

Authors:  Y Manabe; T Tsubota; Y Haruta; M Okazaki; S Haisa; K Nakamura; I Kimura
Journal:  Biochem Pharmacol       Date:  1984-07-01       Impact factor: 5.858

7.  Chimeric toxins: toxic, disulfide-linked conjugate of concanavalin A with fragment A from diphtheria toxin.

Authors:  D G Gilliland; R J Collier; J M Moehring; T J Moehring
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

8.  Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier.

Authors:  L Chedid; M Parant; F Parant; F Audibert; F Lefrancier; J Choay; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

9.  Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.

Authors:  S Ramakrishnan; L L Houston
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

10.  beta-Endorphin: synthesis and properties of analogs modified in positions 8 and 31.

Authors:  D Yamashiro; P Nicolas; C H Li
Journal:  Int J Pept Protein Res       Date:  1982-07
View more
  3 in total

1.  Transport of thyrotropin releasing hormone in rabbit buccal mucosa in vitro.

Authors:  M E Dowty; K E Knuth; B K Irons; J R Robinson
Journal:  Pharm Res       Date:  1992-09       Impact factor: 4.200

2.  A comparison of peptidase activities and peptide metabolism in cultured mouse keratinocytes and neonatal mouse epidermis.

Authors:  P K Shah; R T Borchardt
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

3.  Oral absorption of peptides: influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues.

Authors:  D I Friedman; G L Amidon
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.